C2N Diagnostics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its PrecivityAD2 blood test, designed to aid in the diagnosis of Alzheimer’s diseaseAlzheimer’s disease in patients aged 55 and older experiencing cognitive decline. This marks the first global regulatory approval for a blood test specifically for Alzheimer’s disease diagnosis. The test analyzes multiple blood components to determine the likelihood of amyloid plaque presence in the brain, a key indicator of Alzheimer’s.
This approval is particularly important for the UK, which has a high prevalence of Alzheimer’s disease and limited access to traditional diagnostic methods like PET scans. The availability of a less invasive and more accessible blood test could significantly improve early diagnosis rates and facilitate timely interventions, ultimately impacting patient outcomes and healthcare resource allocation. Early diagnosis not only enables lifestyle changes that may delay disease progression, but also allows for more informed treatment decisions and participation in clinical trials.
The PrecivityAD2 test has demonstrated strong clinical performance in studies, with a recent publication showing 92% negative predictive value and 91% positive predictive value using a single cutoff, and 95% for both using a two-cutoff approach. This performance surpasses recent expert consensus recommendations for blood-based Alzheimer’s diagnostic tests, positioning it as a potential alternative to more invasive procedures.
This approval paves the way for broader access to Alzheimer’s diagnostics and represents a significant advancement in the field. It could lead to earlier and more widespread diagnosis, potentially altering the course of the disease for many individuals and reducing the overall burden on healthcare systems grappling with the growing prevalence of Alzheimer’s. The increased accessibility to accurate testing may also accelerate research and development of new treatments as more patients are identified and enrolled in clinical trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
